• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

An Oleanolic Acid Derivative Inhibits Hemagglutinin-Mediated Entry of Influenza A Virus

tetano

Editor, Senior Moderator
Viruses. 2020 Feb 18;12(2). pii: E225. doi: 10.3390/v12020225. [h=1]An Oleanolic Acid Derivative Inhibits Hemagglutinin-Mediated Entry of Influenza A Virus.[/h]
Ye M[SUP]1,[/SUP][SUP]2[/SUP], Liao Y[SUP]3[/SUP], Wu L[SUP]2[/SUP], Qi W[SUP]2[/SUP], Choudhry N[SUP]1,[/SUP][SUP]2[/SUP], Liu Y[SUP]1,[/SUP][SUP]2[/SUP], Chen W[SUP]4[/SUP], Song G[SUP]3[/SUP], Chen J[SUP]1,[/SUP][SUP]2[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Influenza A viruses (IAV) have been a major public health threat worldwide, and options for antiviral therapy become increasingly limited with the emergence of drug-resisting virus strains. New and effective anti-IAV drugs, especially for highly pathogenic influenza, with different modes of action, are urgently needed. The influenza virus glycoprotein hemagglutinin (HA) plays critical roles in the early stage of virus infection, including receptor binding and membrane fusion, making it a potential target for the development of anti-influenza drugs. In this study, we show that OA-10, a newly synthesized triterpene out of 11 oleanane-type derivatives, exhibited significant antiviral activity against four different subtypes of IAV (H1N1, H5N1, H9N2 and H3N2) replications in A549 cell cultures with EC[SUB]50[/SUB] ranging from 6.7 to 19.6 μM and a negligible cytotoxicity (CC[SUB]50[/SUB] > 640 μM). It inhibited acid-induced hemolysis in a dose-dependent manner, with an IC[SUB]50[/SUB] of 26 ?M, and had a weak inhibition on the adsorption of H5 HA to chicken erythrocytes at higher concentrations (≥40 ?M). Surface plasmon resonance (SPR) analysis showed that OA-10 interacted with HA in a dose-dependent manner with the equilibrium dissociation constants (KD) of the interaction of 2.98 ? 10[SUP]-12[/SUP] M. Computer-aided molecular docking analysis suggested that OA-10 might bind to the cavity in HA stem region which is known to undergo significant rearrangement during membrane fusion. Our results demonstrate that OA-10 inhibits H5N1 IAV replication mainly by blocking the conformational changes of HA2 subunit required for virus fusion with endosomal membrane. These findings suggest that OA-10 could serve as a lead for further development of novel virus entry inhibitors to prevent and treat IAV infections.


[h=4]KEYWORDS:[/h] hemagglutinin (HA); influenza A virus (IAV); oleanane-type derivatives; virus entry inhibitors

PMID: 32085430 DOI: 10.3390/v12020225
 
Back
Top Bottom